|
Product class:
|
Medicinal product with marketing authorization
|
|
Medicinal product class:
|
Human medicine
|
|
Name of medicinal product:
|
ARANESP
|
|
Active substances:
|
|
|
ATC code:
|
B03XA02
|
|
Dosage form:
|
solution for injection in pre-filled syringe
|
|
Strength:
|
15mcg 0.375ml
|
|
Legal status for supply*:
|
Subject to medicinal prescription
|
|
Summary of product characteristics (SPC):
|
|
|
Package information leaflet (PIL):
|
EST
|
|
Labelling:
|
|
|
Indication:
|
Treatment of symptomatic anaemia associated with chronic renal failure (CRF) in adults and
paediatric patients (see section 4.2).
Treatment of symptomatic anaemia in adult cancer patients with non-myeloid malignancies receiving
chemotherapy.
|
|
Safety features:
|
Yes
|
|
Marketing authorization holder:
|
Amgen Europe B.V.
|
|
Marketing authorization number:
|
EU/1/01/185
|
|
Marketing authorization issued on:
|
June 8, 2001
|
|
Marketing authorization expires on:
|
Unlimited
|
|
Marketing authorization procedure type:
|
Centralised
|
|
Assessment report:
|
|
|
Package code
|
Name of medicinal product
|
Dosage form
|
Package
|
Legal status
|
Reimbursements
|
Reference price
|
Last imported
|
PƤritolumaa
|
Additional information
|
|
1207257
|
ARANESP
|
solution for injection in pre-filled syringe
|
15mcg 0.375ml 0.375ml 1TK
|
Prescription
|
|
|
|
|
|
|
1207268
|
ARANESP
|
solution for injection in pre-filled syringe
|
15mcg 0.375ml 0.375ml 4TK
|
Prescription
|
|
|
|
|
|
Legal status for supply – medicinal product on medical prescription or not subject to medical prescription
You can download Acrobat Reader fromhere